These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

787 related articles for article (PubMed ID: 30377198)

  • 1. Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis.
    Labadie BW; Bao R; Luke JJ
    Clin Cancer Res; 2019 Mar; 25(5):1462-1471. PubMed ID: 30377198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy.
    Fujiwara Y; Kato S; Nesline MK; Conroy JM; DePietro P; Pabla S; Kurzrock R
    Cancer Treat Rev; 2022 Nov; 110():102461. PubMed ID: 36058143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives.
    Peyraud F; Guegan JP; Bodet D; Cousin S; Bessede A; Italiano A
    Front Immunol; 2022; 13():807271. PubMed ID: 35173722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine.
    Campesato LF; Budhu S; Tchaicha J; Weng CH; Gigoux M; Cohen IJ; Redmond D; Mangarin L; Pourpe S; Liu C; Zappasodi R; Zamarin D; Cavanaugh J; Castro AC; Manfredi MG; McGovern K; Merghoub T; Wolchok JD
    Nat Commun; 2020 Aug; 11(1):4011. PubMed ID: 32782249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities.
    Cheong JE; Sun L
    Trends Pharmacol Sci; 2018 Mar; 39(3):307-325. PubMed ID: 29254698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indoleamine 2, 3-Dioxygenase 1 Mediates Survival Signals in Chronic Lymphocytic Leukemia
    Atene CG; Fiorcari S; Mesini N; Alboni S; Martinelli S; Maccaferri M; Leonardi G; Potenza L; Luppi M; Maffei R; Marasca R
    Front Immunol; 2022; 13():832263. PubMed ID: 35371054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of IDO-Kynurenine-AhR Axis Ameliorated Colitis-Associated Colon Cancer via Inhibiting Immune Tolerance.
    Zhang X; Liu X; Zhou W; Du Q; Yang M; Ding Y; Hu R
    Cell Mol Gastroenterol Hepatol; 2021; 12(4):1179-1199. PubMed ID: 34087454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kynurenine produced by indoleamine 2,3-dioxygenase 2 exacerbates acute liver injury by carbon tetrachloride in mice.
    Hoshi M; Osawa Y; Nakamoto K; Morita N; Yamamoto Y; Ando T; Tashita C; Nabeshima T; Saito K
    Toxicology; 2020 May; 438():152458. PubMed ID: 32289347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond.
    Muller AJ; Manfredi MG; Zakharia Y; Prendergast GC
    Semin Immunopathol; 2019 Jan; 41(1):41-48. PubMed ID: 30203227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy.
    Shi J; Chen C; Ju R; Wang Q; Li J; Guo L; Ye C; Zhang D
    J Immunother Cancer; 2019 Sep; 7(1):246. PubMed ID: 31511064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy.
    Zhai L; Spranger S; Binder DC; Gritsina G; Lauing KL; Giles FJ; Wainwright DA
    Clin Cancer Res; 2015 Dec; 21(24):5427-33. PubMed ID: 26519060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1-Methyl-D-tryptophan activates aryl hydrocarbon receptor, a pathway associated with bladder cancer progression.
    Matheus LHG; Dalmazzo SV; Brito RBO; Pereira LA; de Almeida RJ; Camacho CP; Dellê H
    BMC Cancer; 2020 Sep; 20(1):869. PubMed ID: 32907554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indoleamine 2,3-Dioxygenase Activity-Induced Acceleration of Tumor Growth, and Protein Kinases-Related Novel Therapeutics Regimens.
    Engin AB; Engin A
    Adv Exp Med Biol; 2021; 1275():339-356. PubMed ID: 33539022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IDO1/TDO dual inhibitor RY103 targets Kyn-AhR pathway and exhibits preclinical efficacy on pancreatic cancer.
    Liang H; Li T; Fang X; Xing Z; Zhang S; Shi L; Li W; Guo L; Kuang C; Liu H; Yang Q
    Cancer Lett; 2021 Dec; 522():32-43. PubMed ID: 34520819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO.
    Kim M; Tomek P
    Front Immunol; 2021; 12():636081. PubMed ID: 33708223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-γ induces a tryptophan-selective amino acid transporter in human colonic epithelial cells and mouse dendritic cells.
    Bhutia YD; Babu E; Ganapathy V
    Biochim Biophys Acta; 2015 Feb; 1848(2):453-62. PubMed ID: 25450809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of neuroblastoma cells through Kynurenine-AHR pathway inhibition.
    Dos Santos IL; Mitchell M; Nogueira PAS; Lafita-Navarro MC; Perez-Castro L; Eriom J; Kilgore JA; Williams NS; Guo L; Xu L; Conacci-Sorrell M
    FEBS J; 2024 May; 291(10):2172-2190. PubMed ID: 38431776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tryptophan and its metabolites in normal physiology and cancer etiology.
    Perez-Castro L; Garcia R; Venkateswaran N; Barnes S; Conacci-Sorrell M
    FEBS J; 2023 Jan; 290(1):7-27. PubMed ID: 34687129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of indoleamine 2,3-dioxygenase 1 (IDO1) and kynurenine pathway in the regulation of the aging process.
    Salminen A
    Ageing Res Rev; 2022 Mar; 75():101573. PubMed ID: 35085834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn-AhR-AQP4 signaling pathway.
    Du L; Xing Z; Tao B; Li T; Yang D; Li W; Zheng Y; Kuang C; Yang Q
    Signal Transduct Target Ther; 2020 Feb; 5(1):10. PubMed ID: 32296044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.